drugset
drugset / Trial / NCT05999968

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

NCT05999968 ↗

Phase 1 Terminated 10 enrolled Eli Lilly and Company Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months.

Timeline

Start
2024-01-12
Primary completion
2024-02-23
Completion
2026-01-21

Outcome

Outcome not reported

Stopped: “The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary endpoint.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule — Oral
Background Darolutamide Other / unclassified — Oral

Indications

prostate neoplasm